Under Construction:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only
      Prescribing Information
      BOTOX® SMPC
      RESOURCES

      +30 YEARS' GLOBAL EXPERIENCE
      ACROSS MULTIPLE INDICATIONS1-4

       

      UROLOGY

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.5
      Prescribing Information
      BOTOX® SMPC
      RESOURCES

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

      UROLOGY

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.5

      UK-BUO-240019. DOP: April 2024.

      The Patient Experience: Overactive bladder (OAB) can impact on patients' quality of life in many ways

      Definition of OAB: OAB is characterised by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia6,7

      patient exp image 1

      URINARY INCONTINENCE (UI):

      • urgency UI:7 involuntary leakage accompanied by urgency
      • stress UI:7 involuntary leakage on effort or exertion, or on sneezing or coughing
      • mixed UI:7 involuntary leakage associated with urgency and also with exertion, effort, sneezing or coughing
      patient exp image 1

      URINARY INCONTINENCE (UI):

      • urgency UI:7 involuntary leakage accompanied by urgency
      • stress UI:7 involuntary leakage on effort or exertion, or on sneezing or coughing
      • mixed UI:7 involuntary leakage associated with urgency and also with exertion, effort, sneezing or coughing

      The impacts of OAB on patient quality of life are manifold8-16

      X1470 OAB UK BOTOX Sales Aid - New Branding_32
      X1470 OAB UK BOTOX Sales Aid - New Branding_32

      Impact of OAB on daily living

      2 out of 3 patients report that their symptoms affect their daily life17

      *CES-D: Center for Epidemiological Studies – Depression. The CES-D is a self-reported depression scale including 20 items, developed to identify depression-related symptoms. Scores range from 0 to 60, with higher scores relating to more depression-related symptoms, and scores of 16 or over indicating depression.14

      CES-D: Center for Epidemiological Studies - Depression; OAB: overactive bladder; UI: urinary incontinence.

      LEARN ABOUT THE MANAGEMENT OF OAB

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed April 2024.
      6. Abrams P, Cardozo L et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178
      7. Milsom I. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal (AI) incontinence. Abrams P et al. Incontinence: 6th edition. 2017:50
      8. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2-6
      9. Coyne K S, Payne C et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455-463
      10. Abrams P, Kelleher C J et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580-590
      11. Du Moulin M F, Hamers J P et al. Prevalence of urinary incontinence among community-dwelling adults receiving home care. Res Nurs Health. 2008;31(6):604-612
      12. Zorn B H, Montgomery H et al. Urinary incontinence and depression. J Urol. 1999;162(1):82-84
      13. Irwin D E, Milsom I et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96-100
      14. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      15. Papanicolaou S, Hunskaar S et al. Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int. 2005;96(6):831-838
      16. Rigby D. Urinary urge incontinence: causes and management strategies. Br J Community Nurs. 2005;10(4):172, 174-178
      17. Milsom I, Abrams P et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766
      18. Temml C, Haidinger G et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn. 2000;19(3):259-271

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed April 2024.
      6. Abrams P, Cardozo L et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178
      7. Milsom I. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal (AI) incontinence. Abrams P et al. Incontinence: 6th edition. 2017:50
      8. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2-6
      9. Coyne K S, Payne C et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455-463
      10. Abrams P, Kelleher C J et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580-590
      11. Du Moulin M F, Hamers J P et al. Prevalence of urinary incontinence among community-dwelling adults receiving home care. Res Nurs Health. 2008;31(6):604-612
      12. Zorn B H, Montgomery H et al. Urinary incontinence and depression. J Urol. 1999;162(1):82-84
      13. Irwin D E, Milsom I et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96-100
      14. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      15. Papanicolaou S, Hunskaar S et al. Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int. 2005;96(6):831-838
      16. Rigby D. Urinary urge incontinence: causes and management strategies. Br J Community Nurs. 2005;10(4):172, 174-178
      17. Milsom I, Abrams P et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766
      18. Temml C, Haidinger G et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn. 2000;19(3):259-271

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      Date of preparation: April 2024. UK-BUO-240022.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.